Other formats:
BibTeX
LaTeX
RIS
@article{1300333,
author = {Kissová, Jarmila and Ovesná, Petra and Buliková, Alena and Zavřelová, Jiřina and Penka, Miroslav},
article_location = {Philadelphia},
article_number = {4},
doi = {http://dx.doi.org/10.1097/MBC.0000000000000293},
keywords = {microparticle; myeloproliferative neoplasms; procoagulant activity; thrombosis},
language = {eng},
issn = {0957-5235},
journal = {BLOOD COAGULATION & FIBRINOLYSIS},
title = {Increasing procoagulant activity of circulating microparticles in patients with Philadelphia-negative myeloproliferative neoplasms: a single-centre experience},
volume = {26},
year = {2015}
}
TY - JOUR
ID - 1300333
AU - Kissová, Jarmila - Ovesná, Petra - Buliková, Alena - Zavřelová, Jiřina - Penka, Miroslav
PY - 2015
TI - Increasing procoagulant activity of circulating microparticles in patients with Philadelphia-negative myeloproliferative neoplasms: a single-centre experience
JF - BLOOD COAGULATION & FIBRINOLYSIS
VL - 26
IS - 4
SP - 448-453
EP - 448-453
PB - Lippincott Williams & Wilkins
SN - 09575235
KW - microparticle
KW - myeloproliferative neoplasms
KW - procoagulant activity
KW - thrombosis
N2 - Microparticles are small membrane fragments with dimension between 0.1 and 1 mu m, which are released during cell activation or apoptosis, exposing the phospholipid phosphatidylserine and membrane antigens typical for cellular origin. Philadelphia-negative myeloproliferative neoplasms (MPNs) are characterized by an increased risk of thrombosis. Data from literature suggest an association between thrombosis and the procoagulant activity of microparticles. Association between the procoagulant activity of microparticles and the incidence of thrombosis was assesed in a group of 126 patients with Philadelphia-negative MPNs. Measurement of microparticles procoagulant activity was performed using a functional assay, namely the Zymuphen MP-activity (Hyphen Biomed, Neuville-sur-oise, France). A total of 539 samples were analysed within this group of patients, regardless of patients' state of health. A significantly higher circulating microparticles procoagulant activity was found in MPN patients as compared with the control group (P<0.001). A pathological level of procoagulant activity was observed more frequently in patients with polycythaemia vera (88%, P=0.002) than groups of patients with essential thrombocythaemia (73.2%) and primary myelofibrosis (68.3%); the same result was confirmed in patients with a history of venous thrombosis in comparison with patients without thrombosis (84.7 vs. 73.2%, P=0.029). Patients without cytoreductive treatment had a higher activity of microparticles (P=0.010). Furthermore, presence of JAK2 V617F mutation was associated with an increased procoagulant activity (P=0.007), as well as the higher JAK2 V617F allele burden (P=0.001). Further prospective clinical studies will be necessary to evaluate the clinical relevance of microparticles in the prediction hypercoagulable state in these patients.
ER -
KISSOVÁ, Jarmila, Petra OVESNÁ, Alena BULIKOVÁ, Jiřina ZAVŘELOVÁ and Miroslav PENKA. Increasing procoagulant activity of circulating microparticles in patients with Philadelphia-negative myeloproliferative neoplasms: a single-centre experience. \textit{BLOOD COAGULATION \&{} FIBRINOLYSIS}. Philadelphia: Lippincott Williams \&{} Wilkins, 2015, vol.~26, No~4, p.~448-453. ISSN~0957-5235. Available from: https://dx.doi.org/10.1097/MBC.0000000000000293.
|
